Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Anetumab Ravtansine vs Bevacizumab + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT03587311Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2018
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of anetumab ravtansine in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Oct 2018; status: active, not recruiting.
02
Drugs
anetumab ravtansine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03587311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03587311.